Kadmon Shares Rise 72% After Sanofi Bid of $9.50 a Share
09 9월 2021 - 12:23AM
Dow Jones News
By Chris Wack
Kadmon Holdings Inc. shares were up 73% to $9.15 Wednesday after
Sanofi SA said it was buying the biopharmaceutical company for
$9.50 a share in cash, which represents a total equity value of
$1.9 billion.
Volume for the stock was 49.5 million shares at 10:45 a.m. ET,
compared with 65-day average volume of 3.7 million shares. The
stock hit a 52-week high of $9.20 earlier in the session.
Kadmon's pipeline includes drug candidates for immune and
fibrotic diseases, as well as immuno-oncology therapies.
The transaction is expected to be modestly dilutive to Sanofi's
earnings in 2022.
The offer price represents a premium of 79% over Tuesday's
closing price, and a premium of 113% over the 60 trading days
volume-weighted average price.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 08, 2021 11:08 ET (15:08 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Kadmon (NASDAQ:KDMN)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Kadmon (NASDAQ:KDMN)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Kadmon Holdings Inc (나스닥)의 실시간 뉴스: 최근 기사 0
More Kadmon Holdings Inc News Articles